{"id":"W3088717396","doi":"10.1080/21678421.2020.1822410","title":"A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS","year":2020,"lang":"nl","type":"article","venue":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration","topic":"Amyotrophic Lateral Sclerosis Research","field":"Medicine","cited_by":56,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; London Health Sciences Centre; Centre Hospitalier de l’Université de Montréal; University of Calgary; University of Saskatchewan; University of Alberta; Université Laval; University of Toronto; Montreal Neurological Institute and Hospital","funders":"National Center for Advancing Translational Sciences; Cytokinetics; CA Technologies; Astellas Foundation for Research on Metabolic Disorders; Astellas Pharma US","keywords":"Medicine; Placebo; Internal medicine; Tolerability; Statistical significance; Clinical endpoint; Nausea; Discontinuation; Adverse effect; Renal function; Dose-ranging study; Amyotrophic lateral sclerosis; Randomized controlled trial; Double blind","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001256637,0.0008691575,0.00265,0.0003365763,0.0002456261,0.000282137,0.0003181709,0.0005609538,0.0004407149],"category_scores_gemma":[0.0001393424,0.0006372567,0.0004084611,0.0008780539,0.0006245052,0.000985808,0.0002171289,0.0008162023,0.00006936365],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002526691,"about_ca_system_score_gemma":0.0002738564,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002322404,"about_ca_topic_score_gemma":0.0001225997,"domain_scores_codex":[0.9929423,0.0008971961,0.002238736,0.001288089,0.001580023,0.001053679],"domain_scores_gemma":[0.997206,0.0001477313,0.0008417277,0.000537896,0.0004681448,0.0007985162],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9670153,0.002506422,0.01499056,0.0003251888,0.0004253053,0.00002496999,0.001332512,0.0002684874,0.009079016,0.0002512246,0.0004265681,0.003354393],"study_design_scores_gemma":[0.9558994,0.009675582,0.02240339,0.0009273833,0.0004704822,0.000001312045,0.00003777726,0.008877241,0.0008946392,0.00004370617,0.00007096174,0.0006980814],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850242,0.001718522,0.0003904867,0.004714101,0.0003802894,0.00741207,0.0001039732,0.00006168004,0.0001946718],"genre_scores_gemma":[0.9951378,0.001348482,0.0005927181,0.0006772187,0.001010912,0.0003209365,0.0005388816,0.0001250544,0.0002479685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01111591,"threshold_uncertainty_score":0.9996079,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06039995687883074,"score_gpt":0.2916062694905002,"score_spread":0.2312063126116695,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}